Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP

We recently compiled a list of the Top 10 Boring Stocks That Make Money. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the most boring stocks.

TheFly reported on March 12 that Wedbush raised its price target on DNTH to $103 from $80 while reiterating an Outperform rating. The firm updated its estimates following the company’s recent secondary offering, factoring in the $675 million capital raise and assuming full exercise of the overallotment option. While awaiting more detailed CAPTIVATE data, Wedbush expects Claseprubart could show stronger response rates and more convenient dosing than riliprubart, which may support its competitive position in CIDP.

Additionally, on March 12, Dianthus Therapeutics, Inc. (NASDAQ:DNTH) announced that it completed its previously announced upsized underwritten public offering, raising about $719 million in gross proceeds before fees and expenses. The transaction included 8.47 million common shares, reflecting the full exercise of the underwriters’ option for additional shares, along with pre-funded warrants issued to certain investors in place of common stock.

DNTH said the capital will support its clinical and preclinical pipeline, preparations for potential commercialization, and general corporate needs. The financing meaningfully strengthens the company’s balance sheet as it advances next-generation treatments for severe autoimmune diseases and expands its development efforts across key programs.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a clinical-stage biotech company developing antibody therapies for severe autoimmune and inflammatory diseases.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. 

Disclosure: None. Follow Insider Monkey on Google News.